Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings
Sign Up to like & getrecommendations! Published in 2020 at "Quality of Life Research"
DOI: 10.1007/s11136-020-02520-7
Abstract: Background Pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are approved advanced melanoma (AM) immunotherapies. To address limited health-related quality of life (QoL) real-world evidence with immunotherapies in AM, we compared QoL in AM patients receiving either treatment… read more here.
Keywords: real world; ipi nivo; clinical practice; health ... See more keywords
Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz255.041
Abstract: Abstract Background In phase III trials, the results of ipilimumab plus nivolumab combination therapy (IPI+NIVO) are promising for metastatic melanoma (MM), despite many treatment-related grade 3-4 adverse events (AEs). Here, we report real-world outcomes of… read more here.
Keywords: ipi nivo; bms advisory; advisory consultancy; 1st line ... See more keywords
OP0003 Rheumatic immune related adverse events of checkpoint therapy for cancer: case series of an emerging nosologic entity
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1628
Abstract: Background Immune checkpoint therapy is a major advance in the field of oncology. Agents targeting CTLA-4, programmed cell death protein 1 (PD-1) and PD-ligand 1 have produced significant survival benefits in patients with malignancies. With… read more here.
Keywords: prednisone; melanoma; ipi nivo; ipi ... See more keywords
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005684
Abstract: Background Adjuvant therapy for high-risk resected melanoma with programmed cell-death 1 blockade results in a median relapse-free survival (RFS) of 5 years. The addition of low dose ipilimumab (IPI) to a regimen of adjuvant nivolumab… read more here.
Keywords: high risk; resected melanoma; adjuvant nivolumab; ipi nivo ... See more keywords
Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes.
Sign Up to like & getrecommendations! Published in 2020 at "JCI insight"
DOI: 10.1172/jci.insight.137066
Abstract: BACKGROUND The reshaping of the immune landscape by nivolumab (NIVO) and ipilimumab (IPI) and its relation to patient outcomes is not well-described. METHODS We used high-parameter flow cytometry and a novel computational platform, CytoBrute, to… read more here.
Keywords: ipi nivo; ipi; response; immune landscape ... See more keywords
Preoperative checkpoint inhibition (CPI) and cryoablation (Cryo) in women with early-stage breast cancer (ESBC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.592
Abstract: 592 Background: Checkpoint inhibition (CPI) combined with local strategies that cause local tumor destruction, such as cryo may augment tumor specific immunity and improve survival. We previously demonstrated in 18 ESBC patients (pts) that pre-operative… read more here.
Keywords: ipi cryo; ipi; ipi nivo; cpi ... See more keywords
Health care resource utilization in patients with advanced melanoma receiving immunotherapies in the real world.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.9532
Abstract: 9532 Background: Both pembrolizumab (PEMBRO) and combination ipilimumab + nivolumab (IPI+NIVO) are FDA-approved immunotherapies for advanced melanoma (AM). These two treatment regimens have different toxicity profiles which may impact health care resource utilization (HCRU). Our… read more here.
Keywords: ipi; ipi nivo; pembro; utilization ... See more keywords
First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.7_suppl.584
Abstract: 584 Background: In mRCC, ipilimumab and nivolumab (ipi-nivo) is a 1L treatment option. Recent data have also shown efficacy of 1L PD(L)1-VEGF (PV) inhibitor combinations. The efficacy of these two strategies has not been compared.… read more here.
Keywords: renal cell; cell carcinoma; combination; ipi nivo ... See more keywords
Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.7_suppl.659
Abstract: 659 Background: Ipi/Nivo is a standard of care for pts with metastatic clear cell RCC. The clinical activity of Ipi/Nivo in patients with metastatic nccRCC remains poorly defined. Methods: Metastatic nccRCC pts who were treated… read more here.
Keywords: pts metastatic; ipi; ipi nivo; clear cell ... See more keywords
Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.7_suppl.669
Abstract: 669 Background: Ipi/Nivo is now FDA approved for the first line treatment of patients (pts) with intermediate and poor risk mRCC but activity in IO refractory mRCC patients is still not well reported. Here we… read more here.
Keywords: therapy; salvage; ipi; ipi nivo ... See more keywords
Real-world time to next treatment (TTNT) for first-line (1L) targeted and immuno-oncology therapies for BRAF-mutated metastatic melanoma (MM) by lactate dehydrogenase (LDH) level.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.8_suppl.141
Abstract: 141 Background: Dabrafenib plus trametinib (D+T), ipilimumab plus nivolumab (I+N), and both nivolumab and pembrolizumab (“PD-1 mono”) are approved for the 1L treatment of MM. This study reports real world 1L TTNT for patients receiving… read more here.
Keywords: initiation; treatment; ipi nivo; ttnt ... See more keywords